Ginkgo Bioworks
DNA
158 hedge funds and large institutions have $214M invested in Ginkgo Bioworks in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 180 closing their positions.
188% more call options, than puts
Call options by funds: $22M | Put options by funds: $7.67M
59.73% more ownership
Funds ownership: 1.36% → 61.1% (+60%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 56
31% less capital invested
Capital invested by funds: $312M → $214M (-$97M)
49% less funds holding
Funds holding: 312 → 158 (-154)
84% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 180
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.22M |
| 2 |
Legal & General Group
London,
United Kingdom
|
+$7.56M |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$4.78M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$7.97M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$5.22M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2.84M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.19M |
DNA Hedge Fund Activity: Q3 2024 in Review
158 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q3 2024, worth a combined $214M — down 31% from $312M a quarter earlier.
Sellers outnumbered buyers: 180 funds closed out of DNA and 29 opened new positions — a net loss of 151 holders — while 56 trimmed existing stakes and 49 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $8.22M. The largest seller was Vanguard Group, cutting an estimated $8.7M.
- 158 institutional investors held Ginkgo Bioworks (DNA) as of Q3 2024, down from 312 in Q2 2024.
- Funds reported $214M of Ginkgo Bioworks stock for Q3 2024, down 31% quarter-over-quarter.
- 29 funds opened new Ginkgo Bioworks positions in Q3 2024 and 180 closed out, a net change of -151 holders.
- The largest Ginkgo Bioworks buyer in Q3 2024 was Opaleye Management, an estimated $8.22M added.
- The largest Ginkgo Bioworks seller in Q3 2024 was Vanguard Group, an estimated $8.7M sold.
Based on aggregated 13F filings for Q3 2024.